Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
Options
BORIS DOI
Publisher DOI
PubMed ID
34344551
Description
This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20-67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive.
Date of Publication
2021-08-23
Publication Type
Article
Subject(s)
Keyword(s)
BNT162b2 mRNA vaccine Greece Immunogenicity Seropositive
Language(s)
en
Contributor(s)
Kontopoulou, Konstantina | |
Ainatzoglou, Alexandra | |
Ifantidou, Athina | |
Goudi, Georgia | |
Antoniadou, Eleni | |
Adamopoulos, Vasilios | |
Papadopoulos, Nikitas | |
Papazisis, Georgios |
Additional Credits
Series
Vaccine
Publisher
Elsevier
ISSN
0264-410X
Access(Rights)
restricted